The UAE pharmaceutical sector is expanding rapidly to meet the evolving needs of a growing population which is expected to reach almost 11.1 million by 2030 according to the world bank projections. This high population growth in addition to increased life expectancy and the prevalence of lifestyle diseases such as diabetes, as well as high aspirations for world-class healthcare services have a direct influence on the growth of the Pharma sector in the UAE and the region.
To achieve sustainable growth for this industry the U.A.E. government entities have adopted a series of long-term plans. The Dubai Industrial Strategy 2030 and the Abu Dhabi vision 2030, for instance, consider the pharmaceutical industry as one of the main priority sub sectors to develop due to its future growth prospects, export potential and mid-term to long-term economic impact.
The UAE government is also focused on minimizing reliance on imported pharmaceuticals. According to data from the UAE Federal Customs Authority, the country is estimated to have imported around 14.9 billion of pharmaceutical products from the world market in 2018. Therefore, developing the local manufacture of pharmaceutical products is becoming one of the main goals of the government, the ministry of health, and legislating authorities. This will also lead to the timely and safe delivery of medical supplies and pharmaceuticals vital for the UAE health sector. These efforts include but are not limited to the Dubai Silk Road Strategy, building an excellent logistics infrastructure, accelerated drug registration systems, in addition to investments in research and development, innovation, and technological advancement.
PHARMA IN HEALTHCARE
12:20 – 12:35
|Value of innovation in pharmaceuticals|
Dr. Martin Price | United Kingdom
Dr. Martin Price | United KingdomVP EMEA Health Economics, Market Access and Reimbursement for Europe, Middle East and Africa, Janssen Pharmaceuticals
Martin leads the team responsible for supporting Janssen operating companies in achieving and maintaining patient access to the company‘s portfolio of innovative products across Europe, Middle East and Africa, a role which he has held for the past six years. Prior to this, he was Director of External Affairs at Janssen UK, where we led a number of functions, including Health Technology Assessment, Market Access, Health Policy, Government Affairs and Communications. During this time, Martin also spent six years as an industry representative of NICE’s Apprasial Committee, which makes recommendations on the availability of medicines in England and Wales. Martin joined Janssen from GlaxoSmithKline, where he worked in the Global Health Outcomes team on products in respiratory and infectious diseases. During his twenty four years in the Pharmaceutical Industry, Martin has gained extensive experience of working with Healthcare Decision-Makers and HTA agencies and was responsible for introducing the first NICE approved patient access scheme into the UK. This innovative risk-sharing arrangement secured a positive NICE decision and national funding for a new oncology medicine. Martin originally qualified as a Clinical Pharmacist working in a busy general hospital, before returning to Academia where he completed a PhD in Health Outcomes Research, whilst continuing to work as a Community Pharmacist.
12:35 – 12:50
|COVID 19: Lessons Learned in the Pharma Industry and a Path Forward|
Ms. Reham Ainudeen | Saudi Arabia
Ms. Reham Ainudeen | Saudi ArabiaDeputy Head, Performance Excellence Department King Fahad Specialist Hospital -Dammam
Clinical Pharmacist graduated from King Abdulaziz University in Jeddah. Worked at IABH Dammam National Guard 2010-2012. Experienced Performance Specialist with a demonstrated history of working in the hospital and healthcare industry. Skilled in Management and Public Speaking. Strong Human Resources professional with advanced skills in conflict resolution. Peace studies and Conflict resolution from George Mason University.
12:50 – 13:05
|Drone-delivered medical supplies|
Mr. Vignesh Santhanam | India
Mr. Vignesh Santhanam | IndiaIndia Lead for Drones and Tomorrow’s Airspace – World Economic Forum
Vignesh is the India Lead for Drones and Tomorrow’s Airspace at the World Economic Forum’s Future of Mobility Platform and has actively been involved in implementing drones in healthcare logistics through the ‘Medicine from the Sky’ initiative. He was the President (2017-2019) and Founding Member of the Drone Federation of India – the voice of India’s UAV industry that focuses on industry advocacy, governance, and policy. In 2018, as part of the DFI, he commissioned the ‘Drone Festival of India’, the biggest commercial UAV conference in the region. Alongside this, he headed Marketing and Digital Initiatives for Quidich Innovation Labs, one of India’s leading UAV companies, based in Mumbai. Prior to UAS, Vignesh was an Information Security Business Analyst with Wipro Technologies where he spent close to three years in Warsaw and Singapore working on BFSI projects prior to pursuing his Management Studies. Post-MBA, he worked with AP Moller-Maersk where he managed B2B initiatives in North Africa, Middle East, and the United States.
13:05 – 13:20
|Pharma Industry Regulatory Collaborations: Opportunities and Challenges|
Dr. Ali Al Sayed | United Arab Emirates
Dr. Ali Al Sayed | United Arab EmiratesDirector of the Pharmaceutical Services Department, DHA
13:20 – 13:30
|Challenge the Experts|
13:30 – 13:45
|Innovation in Real World Evidence: Implications to Evolving Regulatory Landscape|
Ms. Amal Masalmeh | United Arab Emirates
Ms. Amal Masalmeh | United Arab EmiratesClinical Operations Lead-Gulf, EDO Manager-Gulf MAP- NIS-IIT, Grant & RC Champion-Gulf Novartis Middle East FZE
Amal Masalmeh, MSc in Health Care Management from Royal College of Surgeons in Ireland (RCSI). Is currently working as a Clinical Operations Lead and Vendor Center of Excellence Manager for Gulf at Novartis Pharmaceuticals. Amal joined Novartis Pharma in Dubai, UAE in 2011 where her experiences established in building investigator networks and managing interventional and non-interventional clinical trials. Amal successfully achieving the improvement of the clinical research portfolio in terms of site diversity, clinical study management and audit outcomes. On top improving outcomes and oversight on clinical operation processes and vendors selection/approval across the Gulf.
13:45 – 14:00
|COVID-19: Lessons learned in the pharma industry: A Healthcare Provider’s Perspective|
Dr. Lina Reaide | United Arab Emirates
Dr. Lina Reaide | United Arab EmiratesClinical Pharmacist, Clemenceau Medical Center, Dubai
Dr. Lina Reaide, is a PharmD currently practicing as a licensed Clinical Pharmacist in Clemenceau Medical Center, DHCC. Prior to joining CMC Dubai, she spent over 2 years at Clemenceau Medical Center affiliated with Johns Hopkins in Beirut before transferring to their new Dubai Branch last year. She obtained her B.S. in Pharmacy from the Lebanese American University in Lebanon and acquired her PharmD at Houston Methodist Hospital in Texas.
14:00 – 14:15
|Life science collaboration in the Life Sciences ecosystem|
Mr. Bart Van Zijll Langhout | Netherlands
Mr. Bart Van Zijll Langhout | NetherlandsR&D, Campus Lead, Janssen
In his current role Bart leads the Janssen Campus in The Netherlands. As Campus Lead he ensures internal strategic alignment on shared opportunities and interests. As the external face of the Janssen The Netherlands Campus, he represents the Janssen Campus towards internal and external stakeholders to strengthen the position and contribution of the Janssen companies in The Netherlands and establish Janssen as trusted partner and as the preferred Company in Dutch Life Sciences & Health. In addition, Bart is Chairman of the Leiden Bio Science Park Foundation, Member of the Executive Board of the Economic Board Zuid Holland and member of the Advisory Board of HealthHolland. Bart joined Janssen-Cilag The Netherlands in 1988 as a sales representative. Bart became Director Sales and Marketing for Janssen-Cilag The Netherlands in 2000 and Vice-President Sales & Marketing for Janssen-Cilag EMEA in 2003. From 2005 till 2018, Bart has been in Managing Director roles with responsibility for Janssen Switzerland (2005-2009), Janssen Benelux (2009-2012), Crucell (2012-2014) and Janssen Mid-sized markets (2014-2018). In that role Bart was responsible for the commercial activities of Janssen in the Benelux, Nordics, Baltics, Central- & Eastern Europe, Switzerland, Austria, Greece, Malta, Cyprus and Israel. From end-2018 till end-2020, Bart was VP Strategic Alliances EMEA & Janssen The Netherlands Campus Lead establishing a strong Janssen Campus in the Netherlands and successful exporting the Benelux Strategic Alliances concept to other countries in EMEA. Bart holds a PhD in genetics from the State University of Leiden.
14:15 – 14:30
|Challenge the Experts|